Biologic MateR clinical performance test for ADA and TCZ Efficacy prediction

Biologic MateR clinical performance test for ADA and TCZ Efficacy prediction - Biologic MateR clinical performance test for ADA and TCZ Efficacy prediction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015616

Enrollment

300

Registered

2014-11-10

Start date

2014-11-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

Adalimumab plus Methotrexate Tocilizumab plus Methotrexate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: MTX inadequate response patients with RA diagnosed according to the criteria of 1987ACR and 2010ACR/EULAR Aged 20 to 75 years at registration Written informed consent DAS28-ESR score >=3.2 or DAS28-CRP score >=2.7 at the time of entry

Exclusion criteria

Exclusion criteria: Be against the guideline of ADA,TCZ and MTX Patient is otherwise ineligible to participate in this study in the investigator's opinion

Design outcomes

Primary

Measure	Time frame
ADAMTS5mRNA dose at 0wk. Remission rate and ACR response at 24wk.	—

Secondary

Measure	Time frame
SDAI CDAI and Boolean rates at 24wk.	—

Countries

Japan

Contacts

Public ContactStudy Secretariat

NPO Advanced Clinical Research Organization(NPO-ACRO) ACRO

biologic-mate@npo-acro.jp042-352-7676

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026